What's Going On With Huamacyte Shares Tuesday?

Humacyte, Inc. (NASDAQ:HUMA) stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement

Benzinga14:48 ET

Press Release: Humacyte Board of Directors Strengthened With Addition of John P. Bamforth and Keith Anthony Jones

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage

Dow JonesJul 16 08:00 ET

Humacyte Is Maintained at Buy by BTIG

Humacyte Is Maintained at Buy by

Dow JonesJul 15 13:13 ET

Humacyte Price Target Raised to $11.00/Share From $8.00 by BTIG

Humacyte Price Target Raised to $11.00/Share From $8.00 by

Dow JonesJul 15 13:13 ET

MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday.Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin.

BenzingaJul 15 11:04 ET

(HUMA) - Analyzing Humacyte's Short Interest

Humacyte's (NYSE:HUMA) short percent of float has risen 58.68% since its last report. The company recently reported that it has 8.25 million shares sold short, which is 9.14% of all regular shares

BenzingaJul 15 09:00 ET